| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 11.02 | -0.05 (-0.45%) | 5.72 - 14.46 | 51.1 thousand (Below Avg) |
Market data as of 4:00PM 05/24/13. Quotes are delayed by at least 15 min.
| Open | 11.13 |
|---|---|
| Previous Close | 11.07 |
| Day's Range | 10.90 - 11.18 |
| Market Cap | 362.9M |
| Avg Volume (10 Day) | 91.4K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.38 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Pass |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Fail |
| Increased shareholder value? | Fail |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Neutral |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Osiris Therapeutics Announces First Quarter 2013 Financial Results
Business Wire - Tuesday 05/07/2013 8:00 AM ET
Osiris Therapeutics to Present at the 12th Annual Needham Healthcare Conference
Business Wire - Monday 04/29/2013 7:00 AM ET
Osiris Therapeutics Announces First Quarter 2013 Financial Results Conference Call
Business Wire - Thursday 04/25/2013 5:00 PM ET
| OSIR | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -68.64% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.01 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | -- | |
| Price/Sales | 31.66 |
| Company | Last | Change |
|---|---|---|
| Cerus Corp | 5.16 | +0.78% |
| 3SBio Inc | 16.59 | +0.06% |
| Enanta Pharmaceuticals Inc | 20.00 | +0.70% |
| GTX Inc | 5.89 | -9.10% |
| Albany Molecular Research Inc | 11.15 | +0.90% |
Data is delayed by at least 15 min.